Immune cell therapy shows promise for tough leukemia cases
NCT ID NCT04220684
First seen Jan 11, 2026 · Last updated Apr 30, 2026 · Updated 16 times
Summary
This early-stage trial tested whether a special type of immune cell from donors, called natural killer (NK) cells, is safe for people with acute myeloid leukemia (AML) that has returned or not responded to treatment. Nineteen patients received the cells to see the highest safe dose and any side effects. The goal was to find a new way to control the disease without long-term medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Oregon Health & Science University
Portland, Oregon, 24344, United States
Conditions
Explore the condition pages connected to this study.